Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NYSEAMERICAN:APHB NASDAQ:GANX CVE:MPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.05+1.2%$2.22$1.11▼$10.54$39.95M1.631.37 million shs263,755 shsAPHBAmpliphi Biosciences$6.06-14.6%$2.95$0.15▼$1.37$202.82MN/A842,200 shs235,694 shsGANXGain Therapeutics$1.98+0.5%$1.84$1.41▼$2.81$71.18M0.11941,590 shs440,489 shsMPHMedicureC$1.09-0.9%C$1.10C$0.63▼C$1.33C$11.38M1.0216164,087 shs125 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+0.99%+3.02%-7.05%-29.85%-77.87%APHBAmpliphi Biosciences0.00%+9.62%+13.19%+45.40%+51.08%GANXGain Therapeutics+0.51%+5.88%+13.79%+17.16%-26.12%MPHMedicure0.00%0.00%-0.91%-9.17%+23.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.05+1.2%$2.22$1.11▼$10.54$39.95M1.631.37 million shs263,755 shsAPHBAmpliphi Biosciences$6.06-14.6%$2.95$0.15▼$1.37$202.82MN/A842,200 shs235,694 shsGANXGain Therapeutics$1.98+0.5%$1.84$1.41▼$2.81$71.18M0.11941,590 shs440,489 shsMPHMedicureC$1.09-0.9%C$1.10C$0.63▼C$1.33C$11.38M1.0216164,087 shs125 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio+0.99%+3.02%-7.05%-29.85%-77.87%APHBAmpliphi Biosciences0.00%+9.62%+13.19%+45.40%+51.08%GANXGain Therapeutics+0.51%+5.88%+13.79%+17.16%-26.12%MPHMedicure0.00%0.00%-0.91%-9.17%+23.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.20Hold$13.50560.15% UpsideAPHBAmpliphi Biosciences 0.00N/AN/AN/AGANXGain Therapeutics 2.75Moderate Buy$7.86296.83% UpsideMPHMedicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ANVS, GANX, MPH, TILS, and APHB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025GANXGain TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025ANVSAnnovis BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/15/2025GANXGain TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.0010/13/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.0010/8/2025ANVSAnnovis BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025GANXGain TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/7/2025GANXGain TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$5.00 ➝ $7.009/30/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/27/2025ANVSAnnovis BioWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GANXGain TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/8/2025GANXGain TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/A$0.28 per shareN/AMPHMedicureC$23.20M0.49C$0.44 per share2.49C$1.91 per share0.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)APHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AGANXGain Therapeutics-$20.41M-$0.63N/AN/AN/AN/A-289.10%-155.11%11/13/2025 (Estimated)MPHMedicure-C$2.03M-C$0.13N/A∞N/A-9.65%-10.18%-5.63%N/ALatest ANVS, GANX, MPH, TILS, and APHB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025ANVSAnnovis Bio-$0.36N/AN/AN/AN/AN/A11/13/2025Q3 2025GANXGain Therapeutics-$0.15N/AN/AN/AN/AN/A8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/12/2025Q2 2025GANXGain Therapeutics-$0.17-$0.19-$0.02-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AMPHMedicureN/A2.24%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A7.657.65APHBAmpliphi BiosciencesN/AN/AN/AGANXGain Therapeutics0.091.791.79MPHMedicure4.652.031.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%APHBAmpliphi BiosciencesN/AGANXGain Therapeutics11.97%MPHMedicure4.85%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%APHBAmpliphi BiosciencesN/AGANXGain Therapeutics7.18%MPHMedicure26.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableGANXGain Therapeutics2035.95 million33.37 millionOptionableMPHMedicureN/A10.44 millionN/ANot OptionableANVS, GANX, MPH, TILS, and APHB HeadlinesRecent News About These CompaniesMedicure Second Quarter 2025 Earnings: CA$0.08 loss per share (vs CA$0.12 loss in 2Q 2024)August 22, 2025 | finance.yahoo.comMedicure Inc. Reports Increased Revenue and Improved EBITDA for Q2 2025August 20, 2025 | tipranks.comMedicure to Present Financial Results on August 21…August 20, 2025 | pharmiweb.comPMedicure Inc. to Announce Q2 2025 Financial ResultsAugust 18, 2025 | tipranks.comMedicure, Inc.: Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia PharmacyJune 17, 2025 | finanznachrichten.deEarnings call transcript: Medicure reports Q1 2025 decline in revenue, steady stockMay 24, 2025 | uk.investing.comMedicure, Inc.: Medicure Announces Closing of Purchase Agreement for the Acquisition of Gateway Medical PharmacyMarch 11, 2025 | finanznachrichten.deTyreek Hill was driving an estimated 60 mph in a 40 mph zone before hectic detainment incidentSeptember 12, 2024 | nypost.comNMedicure Inc. (NGQ1.F)August 21, 2024 | uk.finance.yahoo.comMedicure Inc. (MPH.V)August 12, 2024 | ca.finance.yahoo.comMPH:CA Medicure Inc.July 26, 2024 | seekingalpha.comPublic Health (Health Services Administration) MPHMay 25, 2024 | buffalo.eduBMaster of Public Health in Social and Behavioral SciencesMay 12, 2024 | uml.eduURochester, United States - Weather Forecasts | Maps | News - Yahoo WeatherMay 5, 2024 | yahoo.comCluj-Napoca, Romania - Weather Forecasts | Maps | News - Yahoo WeatherApril 24, 2024 | yahoo.comMedicure, Inc.: Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO DeficiencyApril 23, 2024 | finanznachrichten.deLiverpool, United Kingdom - Weather Forecasts | Maps | News - Yahoo WeatherApril 22, 2024 | yahoo.comSofia, Bulgaria - Weather Forecasts | Maps | News - Yahoo WeatherApril 21, 2024 | yahoo.comDallas, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 19, 2024 | yahoo.comPrescott, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 18, 2024 | yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Amphenol: The Unseen Giant Behind Every Major Tech TrendBy Jeffrey Neal Johnson | October 8, 2025ANVS, GANX, MPH, TILS, and APHB Company DescriptionsAnnovis Bio NYSE:ANVS$2.04 +0.03 (+1.24%) Closing price 10/24/2025 03:59 PM EasternExtended Trading$2.02 -0.02 (-0.98%) As of 10/24/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Ampliphi Biosciences NYSEAMERICAN:APHB$6.06 -1.04 (-14.65%) As of 10/24/2025AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Gain Therapeutics NASDAQ:GANX$1.98 +0.01 (+0.51%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.00 +0.02 (+0.76%) As of 10/24/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Medicure CVE:MPHC$1.09 -0.01 (-0.91%) As of 10/17/2025Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
